trending Market Intelligence /marketintelligence/en/news-insights/trending/rpCot7m5BDysDuc9AgOJGg2 content esgSubNav
In This List

Allergan fat-removal treatment gets FDA approval for lax tissue in double chin

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Allergan fat-removal treatment gets FDA approval for lax tissue in double chin

Allergan plc said the U.s. Food and Drug Administration cleared ZELTIQ Aesthetics Inc.'s nonsurgical fat reduction CoolSculpting technology to improve the appearance of lax tissue in combination with submental fat, or double chin.

CoolSculpting for the double chin is clinically proven to reduce fat up to 20% in the treated area after one treatment, according to the company.

The company said a clinical study of CoolSculpting in submental fat treatment found that 77% of patients showed an improved appearance of lax tissue and 75% of patients reported their chin looked more toned after treatment.

Allergan acquired ZELTIQ Aesthetics for $2.47 billion in April.